Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1/L2-silenced MiHA-loaded DC Vaccine post allo-SCT
NCT02528682Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2016
- Primary completion
- Mar 2021
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, RNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of minor histocompatibility antigen-loaded programmed death-ligand 1 and programmed death-ligand 2-silenced donor dendritic cell vaccine in hematological malignancy, sponsored by Radboud University Medical Center. Started Jan 2016; status: completed.
02
Drugs
minor histocompatibility antigen-loaded programmed death-ligand 1 and programmed death-ligand 2-silenced donor dendritic cell vaccine
03
Conditions
hematological malignancy
Beyond the preview
Go deeper on NCT02528682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528682.